Table 4.
Daytime sleepiness, colon cancer recurrence, and mortality.
| Daily activities affected by daytime sleepiness | |||||
|---|---|---|---|---|---|
| Almost every day | ≥1 Day/week | Rarely | Never | *Plinear | |
| Disease-free survival | |||||
| # Event/at risk | 18/79 | 32/209 | 92/578 | 49/299 | |
| Age- and caffeine intake-adjusted only, HR (95% CI) | 1.42 (0.83–2.45) | 0.96 (0.62–1.50) | 0.94 (0.66–1.33) | Ref | 0.19 |
| Multivariable-adjusted, HR (95% CI)a | 1.59 (0.92–2.76) | 1.09 (0.69–1.70) | 0.99 (0.70–1.40) | Ref | 0.09 |
| Multivariable-adjusted, HR (95% CI)b | 1.39 (0.79–2.46) | 1.11 (0.70–1.75) | 1.01 (0.71–1.43) | Ref | 0.23 |
| Overall survival | |||||
| # Event/at risk | 10/79 | 22/209 | 38/578 | 23/299 | |
| Age- and caffeine intake-adjusted only, HR (95% CI) | 1.75 (0.83–3.68) | 1.65 (0.92–2.97) | 0.84 (0.50–1.41) | Ref | 0.08 |
| Multivariable-adjusted, HR (95% CI)a | 1.84 (0.86–3.92) | 1.91 (1.05–3.46) | 0.85 (0.51–1.44) | Ref | 0.06 |
| Multivariable-adjusted, HR (95% CI)b | 1.52 (0.70–3.30) | 1.93 (1.05–3.55) | 0.87 (0.51–1.47) | Ref | 0.19 |
*P value for linear trend was tested by assigning each subject the median value of the category and modelled as a continuous variable.
aMultivariable-adjusted model adjusted for age, caffeine intake, sex, T-stage, N-stage, ECOG performance status, and alcohol consumption.
bMultivariable-adjusted model adjusted for age, caffeine intake, sex, T-stage, N-stage, ECOG performance status, alcohol consumption, physical activity, BMI, smoking status, any neuropathy or grade 3+ toxicities during follow-up, and relative dose intensities of fluorouracil and oxaliplatin.